Get the Stockscreener App
86.29
0.65%
0.56
After Hours:
85.50
-0.79
-0.92%
Edwards Lifesciences Corp stock is traded at $86.29, with a volume of 3.60M.
It is up +0.65% in the last 24 hours and down -5.04% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$85.73
Open:
$86.66
24h Volume:
3.60M
Relative Volume:
0.90
Market Cap:
$49.74B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
46.88
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
-2.23%
1M Performance:
-5.04%
6M Performance:
+4.38%
1Y Performance:
+14.64%
1-Day Range:
$84.92
$87.11
1-Week Range:
$84.92
$89.66
52-Week Range:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
US28176EAD0 Bond Profile: Coupon and Redemption - TradingView
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27 - MarketBeat
Wall Street Zen Downgrades Edwards Lifesciences (NYSE:EW) to Hold - MarketBeat
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences (EW) Stock Forecast and Price Target 2026 $EW - MarketBeat
Edwards Lifesciences $39M Securities Class Action Settlement - Claim Depot
EW IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class ActionEW - TMX Newsfile
Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
Edwards Lifesciences stock up 726% in 15 years, beating market - scanx.trade
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions - Yahoo Finance
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead - Yahoo Finance
Edwards Lifesciences stock heads into the open after a 4.1 percent jump - AD HOC NEWS
Is It Too Late to Buy Edwards Lifesciences Corp (EW) After 4.1% Rally? GF Value Says Undervalued - GuruFocus
Edwards Lifesciences Corporation's Stock Price Soars to $89.28, Marking a Strong 4.13% Increase - Smartkarma
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth - Investing.com
Bank of America Corp DE Takes $605.40 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock heads into the open after a mid-80 dollar close - AD HOC NEWS
California State Teachers Retirement System Buys 23,304 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today - Benzinga
Edwards Lifesciences Corp (EW) Stock Analysis: A Potential 19.67% Upside in the Healthcare Sector - DirectorsTalk Interviews
Edwards Lifesciences Insider Daniel Lippis Sells 619 Shares at $87.51 Following Option Exercise - Kalkine Media
Truist raises Edwards Lifesciences target to $95 - scanx.trade
Wall Street Zen Upgrades Edwards Lifesciences (NYSE:EW) to "Buy" - MarketBeat
Insider Daniel Lippis Sells 619 Shares of Edwards Lifesciences C - gurufocus.com
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock By Investing.com - Investing.com Australia
Why Edwards Lifesciences (EW) Stock Is Down Today - Quiver Quantitative
Edwards Lifesciences, Medtronic score CMS win for TAVR - MassDevice
CMS TAVR changes, a boon for Edwards - BioWorld News
Edwards Lifesciences stock price target maintained at $85 by Canaccord - Investing.com Canada
Engineers Gate Manager LP Sells 81,590 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Comments on TAVR National Coverage Decision - Finviz
Edwards Lifesciences maintains 2026 guidance after CMS TAVR NCD - scanx.trade
Edwards Lifesciences stock edges higher after raised 2026 revenue guidance - ad-hoc-news.de
Edwards Lifesciences stock heads into the open after a mild decline - ad-hoc-news.de
EW Stock Quote Price and Forecast - CNN
Can Edwards Lifesciences (NYSE:EW) Withstand Market Pressure? - Kalkine Media
Amundi Decreases Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock heads into the open after a 3.2 percent drop - ad-hoc-news.de
Edwards Lifesciences Corp (EW) Stock Down 3.5% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Edwards Lifesciences Stock Underperforming the Dow? - Yahoo Finance
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) - Seeking Alpha
Azimuth Capital Investment Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
B. Metzler seel. Sohn & Co. AG Lowers Position in Edwards Lifesciences Corporation $EW - MarketBeat
EW Stock Price and Chart — NYSE:EW - TradingView
Nykredit A S Makes New $20.64 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.70%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):